Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 6,000 shares at $20.00 ($120K) on 2024-12-02, disclosed to the SEC on 2024-12-03.
Scheduled sale ($120k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.97 | 1,000 | $20K | 16.6% |
| 2 | $20.00 | 5,000 | $100K | 83.4% |
| Total | $20.00 avg | 6,000 | $120K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |